YU46033B - Novi henigroskopni oblikn,n-dimetil-1-/1-(4-hlorofenil) ciklobutil/-3-metilbuti lamin hlorhidrata - Google Patents

Novi henigroskopni oblikn,n-dimetil-1-/1-(4-hlorofenil) ciklobutil/-3-metilbuti lamin hlorhidrata

Info

Publication number
YU46033B
YU46033B YU205086A YU205086A YU46033B YU 46033 B YU46033 B YU 46033B YU 205086 A YU205086 A YU 205086A YU 205086 A YU205086 A YU 205086A YU 46033 B YU46033 B YU 46033B
Authority
YU
Yugoslavia
Prior art keywords
cyclobutyl
chlorophenyl
dimethyl
henigroscopic
new
Prior art date
Application number
YU205086A
Other languages
English (en)
Serbo-Croatian (sh)
Other versions
YU205086A (en
Inventor
J.E. Jeffery
D. Whybrow
Original Assignee
The Boots Company Plc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10589895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU46033(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Boots Company Plc. filed Critical The Boots Company Plc.
Priority to SI8612050A priority Critical patent/SI8612050A8/sl
Publication of YU205086A publication Critical patent/YU205086A/xx
Publication of YU46033B publication Critical patent/YU46033B/sh
Priority to HRP-2050/86A priority patent/HRP930745B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
YU205086A 1985-12-17 1986-12-02 Novi henigroskopni oblikn,n-dimetil-1-/1-(4-hlorofenil) ciklobutil/-3-metilbuti lamin hlorhidrata YU46033B (sh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SI8612050A SI8612050A8 (sl) 1985-12-17 1986-12-02 Nova nehigroskopična oblika n,n-dimetil-1-1-(4-klorofenil) ciklobutil -3-metilbutilamin klorhidrata
HRP-2050/86A HRP930745B1 (en) 1985-12-17 1993-04-02 New non-hygroscopic form of n,n-dimethyl-1-/1-(4-chlorophenyl) cyclobuthyl)-3-methylbutylamine hydrochloride

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB858531071A GB8531071D0 (en) 1985-12-17 1985-12-17 Therapeutic compound

Publications (2)

Publication Number Publication Date
YU205086A YU205086A (en) 1987-12-31
YU46033B true YU46033B (sh) 1992-12-21

Family

ID=10589895

Family Applications (1)

Application Number Title Priority Date Filing Date
YU205086A YU46033B (sh) 1985-12-17 1986-12-02 Novi henigroskopni oblikn,n-dimetil-1-/1-(4-hlorofenil) ciklobutil/-3-metilbuti lamin hlorhidrata

Country Status (34)

Country Link
US (2) US4929629A (cg-RX-API-DMAC7.html)
EP (1) EP0230742B1 (cg-RX-API-DMAC7.html)
JP (1) JPS62155240A (cg-RX-API-DMAC7.html)
KR (1) KR940008913B1 (cg-RX-API-DMAC7.html)
CN (1) CN1016245B (cg-RX-API-DMAC7.html)
AT (1) ATE56942T1 (cg-RX-API-DMAC7.html)
AU (1) AU601167B2 (cg-RX-API-DMAC7.html)
CA (1) CA1266278A (cg-RX-API-DMAC7.html)
CS (1) CS259545B2 (cg-RX-API-DMAC7.html)
DD (1) DD263050A5 (cg-RX-API-DMAC7.html)
DE (1) DE3674570D1 (cg-RX-API-DMAC7.html)
DK (1) DK170770B1 (cg-RX-API-DMAC7.html)
EG (1) EG17770A (cg-RX-API-DMAC7.html)
ES (1) ES2018163T4 (cg-RX-API-DMAC7.html)
FI (1) FI90413C (cg-RX-API-DMAC7.html)
GB (1) GB8531071D0 (cg-RX-API-DMAC7.html)
GE (1) GEP19970812B (cg-RX-API-DMAC7.html)
GR (1) GR3001069T3 (cg-RX-API-DMAC7.html)
HU (1) HU201901B (cg-RX-API-DMAC7.html)
IE (1) IE59429B1 (cg-RX-API-DMAC7.html)
IL (1) IL80934A (cg-RX-API-DMAC7.html)
IN (1) IN163129B (cg-RX-API-DMAC7.html)
LU (1) LU90865I2 (cg-RX-API-DMAC7.html)
MX (1) MX4684A (cg-RX-API-DMAC7.html)
NL (1) NL300065I1 (cg-RX-API-DMAC7.html)
NO (2) NO165540C (cg-RX-API-DMAC7.html)
NZ (1) NZ218578A (cg-RX-API-DMAC7.html)
PH (1) PH22481A (cg-RX-API-DMAC7.html)
PL (1) PL149519B1 (cg-RX-API-DMAC7.html)
PT (1) PT83958B (cg-RX-API-DMAC7.html)
SU (1) SU1443796A3 (cg-RX-API-DMAC7.html)
UA (1) UA7206A1 (cg-RX-API-DMAC7.html)
YU (1) YU46033B (cg-RX-API-DMAC7.html)
ZA (1) ZA869078B (cg-RX-API-DMAC7.html)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
CA2139000A1 (en) * 1992-06-23 1994-01-06 James W. Young Methods and compositions for treating depression and other disorders using optically pure(+) sibutramine
AU4542893A (en) * 1992-06-23 1994-01-24 Sepracor, Inc. Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
DE4443891A1 (de) 1994-12-09 1996-06-13 Bayer Ag Heterocyclisch substituierte Oxy-phenyl-(phenyl)glycinolamide
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6696495B2 (en) * 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
WO2000043002A1 (en) * 1999-01-20 2000-07-27 Knoll Pharmaceutical Company Method to aid smoking cessation
BG65170B1 (bg) * 1999-03-17 2007-05-31 Knoll Gmbh Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето
US6803387B1 (en) 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
PL351958A1 (en) * 1999-03-19 2003-07-14 Knoll Gmbh Treatment of some tumours associated with gain in weight
US6372798B1 (en) 1999-03-19 2002-04-16 Knoll Pharmaceutical Company Treatment of hyperactivity disorders
AU3896900A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of pain
CA2366660A1 (en) * 1999-03-19 2000-09-28 Carl M. Mendel Treatment of osteoarthritis
WO2000056312A1 (en) 1999-03-19 2000-09-28 Knoll Gmbh Treatment of pulmonary hypertension
US6433020B1 (en) 1999-03-19 2002-08-13 Knoll Pharmaceutical Company Treatment of cardiovascular disease
US6376554B1 (en) 1999-03-19 2002-04-23 Knoll Pharmaceutical Company Method of treating sexual dysfunction
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
US6441046B1 (en) 1999-03-19 2002-08-27 Abbott Gmbh & Co. Kg Control of metabolism
WO2000056319A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of orthostatic hypotension
AU3895300A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of chronic fatigue syndrome
HUP0200501A3 (en) * 1999-03-19 2004-03-29 Abbott Gmbh & Co Kg Use of n,n-dimethyl-1-[1-(4chlorophenyl)cyclobutyl]-3-methylbutylamine for treating sleep apnoea
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6380200B1 (en) 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
US6562974B2 (en) 2000-02-01 2003-05-13 The Procter & Gamble Company Process for making geminal bisphosphonates
PE20011061A1 (es) 2000-02-01 2001-11-20 Procter & Gamble Cristalizacion selectiva del acido 3-piridil-1-hidroxi-etiliden-1,1-bisfosfonico sodio como el hemipentahidrato o el monohidrato
US6232347B1 (en) 2000-03-17 2001-05-15 Knoll Pharmaceutical Company Treatment of osteoarthritis
WO2002083631A1 (en) * 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
ATE486842T1 (de) * 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
MXPA05003355A (es) * 2002-10-05 2005-10-18 Hanmi Pharm Ind Co Ltd Composicion farmaceutica que comprende semihidrato de metansulfonato de sibutramina cristalino.
KR100536750B1 (ko) * 2002-10-05 2005-12-16 한미약품 주식회사 시부트라민 메탄술폰산염의 결정성 반수화물을 포함하는약학 조성물
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
GB0310361D0 (en) * 2003-05-06 2003-06-11 Cipla Ltd Pharmaceutical compound
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
ES2328384T3 (es) * 2004-11-23 2009-11-12 Warner-Lambert Company Llc Derivados del acido 7-(2h-pirazol-3-il)-3,5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de la lipidemia.
WO2006073292A1 (en) 2005-01-06 2006-07-13 Cj Corporation Inorganic acid salts of sibutramine
US8283312B2 (en) * 2005-02-04 2012-10-09 The Research Foundation Of State University Of New York Compositions and methods for modulating body weight and treating obesity-related disorders
KR100781882B1 (ko) * 2005-07-12 2007-12-05 주식회사유한양행 시부트라민을 함유하는 약제학적 조성물
CA2617654A1 (en) * 2005-08-04 2007-02-08 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
US20090203738A1 (en) * 2005-09-22 2009-08-13 Eisai R&D Management Co., Ltd. Pharmaceutical Composition for Treating Bulimia and Depression Arising from Bulimia
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
AU2007219236B2 (en) * 2006-02-23 2012-06-21 Pfizer Limited Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
MX2009002781A (es) 2006-09-15 2009-03-30 Reviva Pharmaceuticals Inc Sintesis, metodos de uso y composiciones de cicloalquilmetilaminas .
CN101583593A (zh) 2006-11-13 2009-11-18 辉瑞产品公司 二芳基、二吡啶基和芳基-吡啶基衍生物及其用途
JP2010510201A (ja) * 2006-11-20 2010-04-02 グレンマーク・ファーマシューティカルズ・エスエー ステアリン酸ＣｏＡ脱飽和酵素阻害剤としてのアセチレン誘導体
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
US20080221057A1 (en) * 2007-02-16 2008-09-11 Wyeth Secreted protein ccdc80 regulates adipocyte differentiation
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
WO2008124120A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent
WO2009037542A2 (en) 2007-09-20 2009-03-26 Glenmark Pharmaceuticals, S.A. Spirocyclic compounds as stearoyl coa desaturase inhibitors
JP5530438B2 (ja) * 2008-08-06 2014-06-25 ファイザー・リミテッド Ｍｃ４作動薬としてのジアゼピンおよびジアゾカン化合物
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
US20120053172A1 (en) 2009-02-12 2012-03-01 Cooperatieve Mirzorg U.A. Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
US8669380B2 (en) 2009-11-02 2014-03-11 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
ES2665467T3 (es) 2010-03-29 2018-04-25 Astellas Pharma Inc. Composición farmacéutica de liberación modificada
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
EA201291384A1 (ru) 2010-07-06 2013-07-30 Астразенека Аб Терапевтические агенты 976
MX366925B (es) 2010-11-04 2019-07-31 Albireo Ab Inhibidores de ibat para el tratamiento de enfermedades hepaticas.
US20130236541A1 (en) 2010-11-08 2013-09-12 Albireo Ab Pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
EP2890370B1 (en) 2012-08-31 2019-10-09 The Regents of the University of California Agents useful for treating obesity, diabetes and related disorders
CN110372522B (zh) * 2019-07-30 2020-10-02 南京工业大学 一种从含有戊二胺的固相中汽提回收戊二胺的方法
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1124485B (de) * 1960-02-12 1962-03-01 Hoechst Ag Verfahren zur Herstellung von analeptisch wirksamen Phenylcycloalkylmethylaminen
SE7600674L (sv) * 1975-02-05 1976-08-06 Rohm & Haas Fungicider
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
US4443449A (en) * 1981-04-06 1984-04-17 The Boots Company Limited Arylcyclobutylalkylamines and anti-depression composition and methods using same
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB2115409B (en) * 1982-02-24 1985-08-07 Zyma Sa Novel crystal modifications of (+)-catechin
DK101683A (da) * 1982-03-12 1983-09-13 Duphar Int Res Phenylpiperazinderivater og fremgangsmaade til fremstilling heraf
IE56001B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylmethylamine compounds
ZA836848B (en) * 1982-09-30 1984-05-30 Boots Co Plc Therapeutic agents
IE56000B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylalkylamine compounds
GB8501192D0 (en) * 1985-01-17 1985-02-20 Boots Co Plc Therapeutic agents
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity

Also Published As

Publication number Publication date
PL263020A1 (en) 1988-05-12
DE3674570D1 (de) 1990-10-31
PT83958A (en) 1987-01-01
CS930586A2 (en) 1988-02-15
DK170770B1 (da) 1996-01-15
SU1443796A3 (ru) 1988-12-07
NO865093D0 (no) 1986-12-16
DK585786A (da) 1987-06-18
FI865030L (fi) 1987-06-18
HU201901B (en) 1991-01-28
MX4684A (es) 1993-12-01
HUT45964A (en) 1988-09-28
EG17770A (en) 1991-03-30
UA7206A1 (uk) 1995-06-30
AU601167B2 (en) 1990-09-06
EP0230742A1 (en) 1987-08-05
NO2005022I1 (no) 2005-10-03
DK585786D0 (da) 1986-12-05
KR870005961A (ko) 1987-07-08
EP0230742B1 (en) 1990-09-26
LU90865I2 (fr) 2002-02-18
NO865093L (no) 1987-06-18
PT83958B (pt) 1989-05-12
IE863102L (en) 1987-06-17
JPH0144176B2 (cg-RX-API-DMAC7.html) 1989-09-26
NL300065I1 (nl) 2001-12-01
YU205086A (en) 1987-12-31
ATE56942T1 (de) 1990-10-15
US4929629A (en) 1990-05-29
NZ218578A (en) 1989-04-26
NO165540B (no) 1990-11-19
PL149519B1 (en) 1990-02-28
CN86108547A (zh) 1987-08-19
IE59429B1 (en) 1994-02-23
FI90413C (fi) 1994-02-10
ZA869078B (en) 1987-07-29
ES2018163T4 (es) 2012-06-14
DD263050A5 (de) 1988-12-21
GEP19970812B (en) 1997-02-10
GB8531071D0 (en) 1986-01-29
IL80934A (en) 1990-07-26
JPS62155240A (ja) 1987-07-10
CA1266278A (en) 1990-02-27
AU6644286A (en) 1987-06-18
IN163129B (cg-RX-API-DMAC7.html) 1988-08-13
GR3001069T3 (en) 1992-03-20
ES2018163B3 (es) 1991-04-01
CS259545B2 (en) 1988-10-14
FI90413B (fi) 1993-10-29
FI865030A0 (fi) 1986-12-10
KR940008913B1 (ko) 1994-09-28
US5068440A (en) 1991-11-26
PH22481A (en) 1988-09-12
CN1016245B (zh) 1992-04-15
NO165540C (no) 1991-02-27

Similar Documents

Publication Publication Date Title
GEP19970812B (en) New non-hygroscopic form of n,n-dimethyl-1-/1-(4-chlorophenyl) cyclobuthyl)-3-methylbutylamine hydrochloride
DK0711154T3 (da) Stabiliseret farmaceutisk præparat indeholdende bupropion
NO20053106D0 (no) Oral, analgesisk doseringsform med forlenget frigivelse.
DE69032679D1 (de) Threo (2R, 3S)-3-amino-2-hydroxypentansäure und threo (2R,3S)-3-(p-methoxy-benzyloxycarbonyl/FMOC) amino-2-hydroxy-pentansäure
MY106315A (en) Pharmaceutical agents
DK0579681T3 (da) Krystallinsk tiagabin-hydrochlorid-monohydrat, dets fremstilling og dets anvendelse
IT1243193B (it) Composizioni farmaceutiche orali a base di melatonina
DE60003943D1 (de) Trimegestone enthaltende pharmazeutische zusammensetzungen
GB2184122B (en) N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate
HUT41002A (en) Process for preparing anticonvulsives
IT9048066A0 (it) 2- amminotetraline-6, 7-sostituite attive come immunomodulanti e composizioni farmaceutiche che le contengono.
IT8619431A0 (it) Composto farmacologicamente attivo e composizioni farmaceutiche che lo contengono, procedimento per prepararlo e intermedio utile in detto procedimento.
IT8420277A0 (it) Dicloridrato di acetildicarnitina, procedimento per la sua preparazione e composizioni farmaceutiche che lo contengono.
HRP930745B1 (en) New non-hygroscopic form of n,n-dimethyl-1-/1-(4-chlorophenyl) cyclobuthyl)-3-methylbutylamine hydrochloride
IT8421627A1 (it) Composizione farmaceutica contenente come ingrediente attivo 24,25-diidrossicolecalciferolo
SE9304065D0 (sv) New compound
ITMI911883A1 (it) Composto con attivita' vasodilatatrice, procedimento per la sua preparazione e composizioni farmaceutiche che lo contengono.
IT1271398B (it) Composizioni farmaceutiche contenenti derivati polipeptidici del ferro per la terapia marziale